Clinical Trial Update: A Study to Evaluate Rocatinlimab (AMG 451) in Adolescent Participants With Moderate-to-severe Atopic Dermatitis (AD) [Phase 3]

View source ↗

Summary

Phase 3 trial completion update for Rocatinlimab (AMG 451) in adolescent patients with moderate-to-severe Atopic Dermatitis.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Atopic Dermatitis

Drugs mentioned

• Rocatinlimab (rocatinlimab)

Snippet

Sponsor: Amgen | Conditions: Atopic Dermatitis | Phase 3 | Status: COMPLETED